Noshaq

Samabriva is Set to Become a World Leader in Precision Biomanufacturing of Complex Molecules With the Announcement of a €4 Million Fundraising Round

Retrieved on: 
Tuesday, December 12, 2023

The French biotechnology company Samabriva has successfully completed a Series-A round of financing to secure an investment of nearly €4 million.

Key Points: 
  • The French biotechnology company Samabriva has successfully completed a Series-A round of financing to secure an investment of nearly €4 million.
  • Alongside their financial investment, they will bring a wealth of knowledge to help transform Samabriva into a leading CDMO.
  • With lead investors like Noshaq and Investsud Tech now on board, this financing round will accelerate Samabriva’s growth.
  • Marina Guillet, CEO of Samabriva - “We’re delighted that leading biotech investors have seen the incredible potential of Samabriva.

Ampacimon Raises $10.6 Million USD in Series C Funding Led by Junction Growth Investors to Accelerate Grid Modernization in the U.S.

Retrieved on: 
Tuesday, October 17, 2023

The round is led by Junction Growth Investors and includes follow-on participation from longstanding investors Korys, Noshaq, Creos, and Gesval.

Key Points: 
  • The round is led by Junction Growth Investors and includes follow-on participation from longstanding investors Korys, Noshaq, Creos, and Gesval.
  • Pieter-Jan Mermans, managing director at Junction Growth Investors, joins Ampacimon’s Board of Directors.
  • “These solutions are critical to grid modernization and to the broad implementation of renewables.
  • “We’re on a mission to accelerate the transition toward a lower emissions world through state-of-the-art grid optimization solutions.

Myocene Announces a Successful Completion of a Bridge Round

Retrieved on: 
Monday, May 29, 2023

LIÈGE, Belgium, May 29, 2023 (GLOBE NEWSWIRE) -- Myocene, the Belgian-based sportstech company, has completed a bridge round of 2M€ in order to finalize a market-ready product, expected mid-2024.

Key Points: 
  • LIÈGE, Belgium, May 29, 2023 (GLOBE NEWSWIRE) -- Myocene, the Belgian-based sportstech company, has completed a bridge round of 2M€ in order to finalize a market-ready product, expected mid-2024.
  • Myocene is a Liège-based start-up that has developed a device for objectifying and measuring muscle fatigue.
  • This innovation, designed for top-level athletes, represents a veritable revolution in the world of sports.
  • “The Myocene device represents a profound change in the way high-level athletes are monitored," adds Dr Pierre Rigaux, Chairman and Founder.

ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors

Retrieved on: 
Thursday, October 20, 2022

GHENT, Belgium, Oct. 20, 2022 /PRNewswire/ -- ExeVir is developing robust therapies providing broad protection against infectious diseases, including coronaviruses. The company has identified high potential candidates harnessing its unique, modular Llama-derived antibody (VHH) technology platform to generate multi-specific antibodies for prophylaxis and treatment against COVID-19. ExeVir is evaluating highly potent heavy chain based antibodies that are unique in targeting both S1 and S2 subunits of the coronavirus spike protein via highly conserved epitopes. Multiple high potential binders offer the potential of heterodimer binders to the spike protein in a molecule or a cocktail.

Key Points: 
  • ExeVir aims to select a final preclinical development candidate before year end 2022 ready for further development in 2023.
  • ExeVir is pleased to announce today the appointment of Dr Jeanne Bolger as Chair to the Board of Directors.
  • We are extremely pleased to welcome Jeanne as Chair of the Board at such a pivotal time for the Company.
  • In addition to its SARS-CoV-2 programs ExeVir has initiated research in dengue, a disease which is rapidly and progressively expanding.

ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors

Retrieved on: 
Thursday, October 20, 2022

GHENT, Belgium, Oct. 20, 2022 /PRNewswire/ -- ExeVir is developing robust therapies providing broad protection against infectious diseases, including coronaviruses. The company has identified high potential candidates harnessing its unique, modular Llama-derived antibody (VHH) technology platform to generate multi-specific antibodies for prophylaxis and treatment against COVID-19. ExeVir is evaluating highly potent heavy chain based antibodies that are unique in targeting both S1 and S2 subunits of the coronavirus spike protein via highly conserved epitopes. Multiple high potential binders offer the potential of heterodimer binders to the spike protein in a molecule or a cocktail.

Key Points: 
  • ExeVir aims to select a final preclinical development candidate before year end 2022 ready for further development in 2023.
  • ExeVir is pleased to announce today the appointment of Dr Jeanne Bolger as Chair to the Board of Directors.
  • We are extremely pleased to welcome Jeanne as Chair of the Board at such a pivotal time for the Company.
  • In addition to its SARS-CoV-2 programs ExeVir has initiated research in dengue, a disease which is rapidly and progressively expanding.

Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainable Growth Strategy and Support of Social Well-Being for its Employees

Retrieved on: 
Wednesday, October 12, 2022

LgiaPark is a new modern complex operating with environmental responsibility and hosts life science companies.

Key Points: 
  • LgiaPark is a new modern complex operating with environmental responsibility and hosts life science companies.
  • Our new location is expected to benefit our employees well-being with better working conditions and a more entrepreneurial culture.
  • The move supports Hyloris commitment to sustainable growth, which we are currently defining in our 2030 ES&G Roadmap.
  • This should enable Hyloris to perform drug formulation and analytical activities, further streamline processes and more effectively capitalise on internal resources.

VistaCare Medical Secures €4 Million to Accelerate the Development and Adoption of Its Solutions for the Management of Serious and Complex Wounds

Retrieved on: 
Wednesday, January 26, 2022

Founded in 2010 in the Jura region, VistaCare Medical develops, produces, and commercializes the VistaCare innovative medical device for the treatment of complex wounds.

Key Points: 
  • Founded in 2010 in the Jura region, VistaCare Medical develops, produces, and commercializes the VistaCare innovative medical device for the treatment of complex wounds.
  • VistaCare offers unrivaled results compared to conventional methods for complex wounds associated with arterial pathologies, burns or other injuries.
  • It improves the quality of life of the patient and allows to treat incurable cases that could lead to amputation.
  • VistaCare Medical is an innovative medtech company developing and commercializing medical devices for its unique wound management platform.

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

Retrieved on: 
Thursday, July 15, 2021

ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.

Key Points: 
  • ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.
  • Under the terms of the collaboration, Mithra will be responsible for upscalingand manufacturing services for filling the drug substance in support of clinical and commercial supply.
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "We are very pleased to collaborate with Mithra which has built a cutting-edge new fill and finish manufacturing facility.
  • Renaat Baes, Chief Manufacturing Officer of Mithra, commented:"We are absolutely thrilled to enter into this collaboration agreement with ExeVir, who is developing promising innovative Covid-19 treatments.

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

Retrieved on: 
Thursday, July 15, 2021

ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.

Key Points: 
  • ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.
  • Under the terms of the collaboration, Mithra will be responsible for upscalingand manufacturing services for filling the drug substance in support of clinical and commercial supply.
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "We are very pleased to collaborate with Mithra which has built a cutting-edge new fill and finish manufacturing facility.
  • Renaat Baes, Chief Manufacturing Officer of Mithra, commented:"We are absolutely thrilled to enter into this collaboration agreement with ExeVir, who is developing promising innovative Covid-19 treatments.

Osivax Secures EUR 8 Million of Financing through a Series A Round to Develop Novel Universal Flu Vaccines and Expand oligoDOM® Technology Platform

Retrieved on: 
Wednesday, July 10, 2019

Osivax was founded in 2017 to translate its innovative oligoDOM technology platform into a vaccine pipeline.

Key Points: 
  • Osivax was founded in 2017 to translate its innovative oligoDOM technology platform into a vaccine pipeline.
  • Currently available seasonal flu vaccines are limited in addressing all flu strains because they target highly variable regions of the virus.
  • Our goal is to establish proof-of-concept on Influenza A and then expand our pipeline to provide a universal flu vaccine.
  • Osivaxs mission is to revolutionize influenza prevention with a universal flu vaccine for both current and future Influenza A and B infections by leveraging its unique oligoDOM technology platform.